2013 ACBS Landline-Cellphone Combined Prevalence Tables
Table 9
TABLE 9. Estimated percent using an inhaled corticosteroid in the past 3 months among adults1 with current2 or active3 asthma status by state/territory – BRFSS Asthma Call-back Survey Land Line And Cell Phone Combined Sample, United States, 2013
State/Territory | Current | Active | ||||||
---|---|---|---|---|---|---|---|---|
Sample size± |
% | SE§ | 95% CI† | Sample size |
% | SE | 95% CI | |
California | 238 | 25.1 | 3.4 | (18.4 – 31.8) | 255 | 27.1 | 3.5 | (20.2 – 34.0) |
Connecticut | 252 | 43.2 | 5.0 | (33.4 – 53.0) | 274 | 38.4 | 4.9 | (28.8 – 48.0) |
Georgia | 144 | 36.2 | 5.8 | (24.8 – 47.6) | 154 | 33.5 | 5.5 | (22.7 – 44.3) |
Hawaii | 189 | 33.2 | 5.3 | (22.8 – 43.6) | 193 | 31.9 | 5.0 | (22.1 – 41.7) |
Indiana | 406 | 35.0 | 3.1 | (28.9 – 41.1) | 429 | 32.8 | 3.0 | (26.9 – 38.7) |
Iowa | 262 | 34.2 | 5.4 | (23.6 – 44.8) | 269 | 32.5 | 5.3 | (22.1 – 42.9) |
Maryland | 264 | 27.1 | 4.0 | (19.3 – 34.9) | 285 | 25.9 | 3.7 | (18.6 – 33.2) |
Michigan | 654 | 40.4 | 2.9 | (34.7 – 46.1) | 702 | 37.8 | 2.8 | (32.3 – 43.3) |
Mississippi | 264 | 31.9 | 4.9 | (22.3 – 41.5) | 270 | 31.9 | 4.8 | (22.5 – 41.3) |
Missouri | 274 | 37.6 | 4.8 | (28.2 – 47.0) | 284 | 35.5 | 4.7 | (26.3 – 44.7) |
Montana | 320 | 32.2 | 4.1 | (24.2 – 40.2) | 348 | 27.9 | 3.9 | (20.3 – 35.5) |
Nebraska | 324 | 30.4 | 4.4 | (21.8 – 39.0) | 350 | 28.0 | 3.9 | (20.4 – 35.6) |
Nevada | 137 | 25.7 | 5.7 | (14.5 – 36.9) | 161 | 23.8 | 5.0 | (14.0 – 33.6) |
New Hampshire | 266 | 31.5 | 4.7 | (22.3 – 40.7) | 281 | 28.5 | 4.4 | (19.9 – 37.1) |
New Jersey | 313 | 32.3 | 4.1 | (24.3 – 40.3) | 349 | 29.3 | 3.8 | (21.9 – 36.7) |
New Mexico | 324 | 33.6 | 3.7 | (26.3 – 40.9) | 343 | 31.6 | 3.6 | (24.5 – 38.7) |
New York | 133 | 19.5 | 5.2 | (9.3 – 29.7) | 136 | 20.6 | 5.3 | (10.2 – 31.0) |
North Carolina | 125 | 40.5 | 6.8 | (27.2 – 53.8) | 140 | 43.7 | 6.5 | (31.0 – 56.4) |
Ohio | 318 | 34.6 | 4.5 | (25.8 – 43.4) | 335 | 32.7 | 4.2 | (24.5 – 40.9) |
Oklahoma | 258 | 31.9 | 4.2 | (23.7 – 40.1) | 264 | 34.3 | 4.3 | (25.9 – 42.7) |
Oregon | 199 | 31.8 | 4.5 | (23.0 – 40.6) | 221 | 29.7 | 4.1 | (21.7 – 37.7) |
Pennsylvania | 313 | 38.1 | 3.7 | (30.8 – 45.4) | 342 | 35.5 | 3.4 | (28.8 – 42.2) |
Texas | 265 | 39.3 | 5.7 | (28.1 – 50.5) | 295 | 36.3 | 5.3 | (25.9 – 46.7) |
Utah | 441 | 29.8 | 3.0 | (23.9 – 35.7) | 460 | 29.7 | 2.9 | (24.0 – 35.4) |
Vermont | 237 | 37.0 | 5.2 | (26.8 – 47.2) | 246 | 38.4 | 5.1 | (28.4 – 48.4) |
Washington | 367 | 31.9 | 3.4 | (25.2 – 38.6) | 374 | 32.8 | 3.4 | (26.1 – 39.5) |
West Virginia | 187 | 34.6 | 4.2 | (26.4 – 42.8) | 189 | 33.6 | 4.2 | (25.4 – 41.8) |
Wisconsin | 265 | 37.6 | 5.1 | (27.6 – 47.6) | 265 | 38.3 | 5.2 | (28.1 – 48.5) |
Puerto Rico | 334 | 28.0 | 3.5 | (21.1 – 34.9) | 402 | 25.9 | 3.1 | (19.8 – 32.0) |
28 state total | 8,073 | 32.0 | 1.2 | (29.6 – 34.4) | 8,616 | 31.5 | 1.1 | (29.3 – 33.7) |
Median | 33.2 | 32.5 | ||||||
Range | 19.5-43.2 | 20.6-43.7 |
1 Aged ≥ 18 years
2 “Yes” response to “Do you still have asthma?”
3 Reported any of the following during the past year: asthma medication use, asthma symptoms, or MD visits for asthma
± Landline and cell phone combined sample size excludes “DK/Refused”
§ Standard error
† Confidence interval